Procept BioRobotics Corp

Research Procept BioRobotics Corp (PRCT) on Bullrun: market cap USD 1.24B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.24B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 308.05M-USD 95.57K-USD 58.34M63.7%-1.72USD 286.50MUSD 51.62MUSD 365.87M
FY2024USD 224.50M-USD 91.41K-USD 103.62M61.1%-1.75USD 333.73MUSD 51.47MUSD 402.22M
FY2023USD 136.19M-USD 105.90K-USD 133.21M52.2%-2.24USD 257.22MUSD 51.34MUSD 280.75M
FY2022USD 75.01M-USD 87.15K-USD 83.04M49.4%-1.96USD 221.86MUSD 51.21MUSD 197.07M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.24Bn/an/an/a
20252025-12-31USD 1.77Bn/an/an/a
20242024-12-31USD 4.41Bn/an/an/a
20232023-12-29USD 2.12Bn/an/an/a
20222022-12-30USD 1.86Bn/an/an/a
20212021-12-31USD 1.09Bn/an/an/a

About Procept BioRobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Procept BioRobotics Corp's market cap?

Procept BioRobotics Corp's market capitalization is USD 1.24B.

What does Procept BioRobotics Corp do?

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.